| Item Type | Name |
|
Academic Article
|
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
|
|
Academic Article
|
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
|
|
Concept
|
Aminobutyrates
|
|
Academic Article
|
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
|
|
Academic Article
|
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
|
|
Academic Article
|
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
|
|
Academic Article
|
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
|
|
Academic Article
|
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
|
|
Academic Article
|
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
|
|
Academic Article
|
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
|
|
Academic Article
|
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
|
|
Academic Article
|
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
|
|
Academic Article
|
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
|
|
Academic Article
|
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
|
|
Academic Article
|
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
|
|
Academic Article
|
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
|
|
Academic Article
|
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
|
|
Academic Article
|
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
|
|
Academic Article
|
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
|
|
Academic Article
|
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
|
|
Academic Article
|
Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization.
|
|
Academic Article
|
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
|
|
Academic Article
|
Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial.
|
|
Academic Article
|
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
|
|
Academic Article
|
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
|
|
Academic Article
|
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
|
|
Academic Article
|
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
|
|
Academic Article
|
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
|
|
Academic Article
|
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
|
|
Academic Article
|
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
|
|
Academic Article
|
Angiotensin Receptor Neprilysin Inhibition?in Heart Failure With Preserved?Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
|
|
Academic Article
|
Health-Related Quality of Life Outcomes in PARADIGM-HF.
|
|
Academic Article
|
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
|
|
Academic Article
|
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
|
|
Academic Article
|
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
|
|
Academic Article
|
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
|
|
Academic Article
|
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
|
|
Academic Article
|
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
|
|
Academic Article
|
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).
|
|
Academic Article
|
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
|
|
Academic Article
|
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
|
|
Academic Article
|
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
|
|
Academic Article
|
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF.
|
|
Academic Article
|
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The?PARADIGM-HF?Trial.
|
|
Academic Article
|
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
|
|
Academic Article
|
Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial.
|
|
Academic Article
|
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
|
|
Academic Article
|
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
|
|
Academic Article
|
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
|
|
Academic Article
|
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
|
|
Academic Article
|
Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction.
|
|
Academic Article
|
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
|
|
Academic Article
|
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart?Failure With Preserved Ejection Fraction.
|
|
Academic Article
|
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
|
|
Academic Article
|
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart?Failure Cause: A PARADIGM-HF Analysis.
|
|
Academic Article
|
Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.
|
|
Academic Article
|
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
|
|
Academic Article
|
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.
|
|
Academic Article
|
Serum potassium in the PARADIGM-HF trial.
|
|
Academic Article
|
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
|
|
Academic Article
|
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
|
|
Academic Article
|
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
|
|
Academic Article
|
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
|
|
Academic Article
|
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
|
|
Academic Article
|
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
|
|
Academic Article
|
Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization.
|
|
Academic Article
|
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
|
|
Academic Article
|
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
|
|
Academic Article
|
Integrating High-Sensitivity Troponin T and?Sacubitril/Valsartan Treatment in?HFpEF: The PARAGON-HF Trial.
|
|
Academic Article
|
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF.
|
|
Academic Article
|
Atrial Fibrillation in Heart?Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
|
|
Academic Article
|
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF.
|
|
Academic Article
|
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
|
|
Academic Article
|
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.
|
|
Academic Article
|
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
|
|
Academic Article
|
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
|
|
Academic Article
|
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
|